Selecta Biosciences Inc. is developing synthetic nanoparticle vaccines designed to mimic invading pathogens in order to elicit an immune response against molecules that would ordinarily be ignored. The company believes its vaccines could be safer, more efficacious and applicable to more diseases than conventional vaccines.

Executive Chairman Robert Bratzler told BioCentury Selecta's targeted Synthetic Vaccine Particle (tSVP) platform combines a pair of discoveries made by the company's three scientific founders, Ulrich von Andrian and Omid Farokhzad at Harvard Medical School, and Robert Langer at Massachusetts Institute of Technology.